Antiretroviral PowerPoint Presentations - PPT
Toolkit for research and development of paediatric antiretroviral drugs and formulations - presentation
Module 10:. Pharmacovigilance. Background – definitions. Timeline of pharmacovigilance for a drug from development (pre-market) to post-marketing use. Burden of adverse drug reactions in children. Number of pharmacoepidemiological safety studies in children (Osokogu et al, 2016).
د. حسين محمد جمعه - presentation
اختصاصي الامراض الباطنة . البورد العربي . كلية طب الموصل . . 2013. Short-Course Antiretroviral Therapy in Primary HIV Infection.
HIV Pharmacotherapy Focused Update - presentation
Drew Lambert, . PharmD. firstname.lastname@example.org. Husson University School of Pharmacy. 1. I have no conflicts of interest.. However, I will be using brand names extensively during the presentation. Majority of the drugs used are brand-only.
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals - presentation
ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice.
Adherence Monitoring in HIV Care - presentation
Simi Padival, MD. November 3, 2016. Objectives. Learn about the importance of assessing adherence to antiretroviral therapy (ART). Learn about the components of assessing for ART adherence. Discuss frequency of monitoring while on ART.
Phylodynamically Estimated HIV Diversification Rates Reveal Prevention of HIV-1 by Antiretroviral T - presentation
Jeffrey B. Joy, Richard H. Liang, Rosemary M. McCloskey, Thuy Nguyen, Chanson J. Brumme, Guillaume Colley, Robert S. Hogg, Julio S.G. Montaner, P. Richard Harrigan, and Art F.Y. Poon. Conflict of Interest.
Public Health Surveillance of Transmitted Antiretroviral Resistance, Oregon 2007 – 2011 - presentation
Sean Schafer MD. May 31, 2012. Three Studies in One. Evaluating antiretroviral drug resistance surveillance in Oregon. Determining frequency of transmitted antiretroviral drug resistance, comparing to U.S..
Traitement antirétroviral précoce - presentation
HIV Cure Research Training Curriculum (. CUREiculum. ). Traitement. . antirétroviral. (ART) . précoce. , module . préparé. par :. . Dr. . Jintanat. . Ananworanich. , U.S. Military HIV Research Program (MHRP).
Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real- - presentation
implementation of Dolutegravir. Meireles MV. , Pascom ARP, Perini F, Rick F, Benzaken A. . Ministry of Health of Brazil, Department of STI, AIDS and Viral Hepatitis. Acknowledgements. No. . conflicts of interest.
HIV Medicine From Guidelines to Practice - presentation
Kiat. . Ruxrungtham. Professor of Medicine, . Chulalongkorn University; and. HIV-NAT, Thai Red Cross AIDS Research Center. Three Decades of HIV/AIDS . Learning and the Future. Mid 1990. 1981. 2012 - 2014.
Antiretroviral Therapy (ART) - presentation
Dr. S . Ntshalintshali. Ngwelezana. hospital. November 2016. HIV prevalence in RSA. The national estimate for HIV prevalence among South Africans in 2012 was 12.2. % (. 95% CI: 11.4–13.1). This estimate is statistically significantly different (p<0.001), from the 2008 national estimate of 10.6% (95% CI: 9.8–11.6). .
Charles B. Hicks, MD Professor of Medicine - presentation
Duke University Medical Center. Durham, North Carolina. New Guidelines, Strategies, and Drugs for Initiation of Antiretroviral Therapy 2013. From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA..
Community Pharmacy Considerations for HIV - presentation
& HCV . Therapy. Larry Pineda, . PharmD. , . PhC. , BCPS, AAHIVP. Visiting Assistant Professor. UNM College of Pharmacy. Conflicts of Interest Disclosure. No conflicts of interest. 2. Learning Objectives – Pharmacist.
The impact of a limited subsidy on access to antiretroviral therapy (ART) and patient outcomes in S - presentation
Barnaby Young. Infectious Diseases registrar. Communicable Diseases Centre,. Institute of Infectious Diseases and . Epidemiology,. Tan Tock . Seng. Hospital, Singapore. Overview. F. inancing of public healthcare in Singapore – and how HIV funding changed in early 2010.
HIV Medication Overview - presentation
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm.
Joseph J. Eron, Jr, MD - presentation
Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Future Directions: Investigational Approaches to Antiretroviral Therapy
Sara - presentation
Lodi. Harvard T.H. Chan School of Public Health. email@example.com. . . . February 25. th. 2016. Recap from earlier today…. We conduct observational studies when a question cannot be answered with a RCT.
Lecture 9-A Infectious - presentation
Diseases. “Human Immunodeficiency Virus. Infection-Antiretroviral . Therapy. ”-1. . Dr. Sabin Thomas, M. Pharm. Ph. D.. Assistant . Professor. in . Pharmacy. Practice. School. of . Pharmacy. , CPN.
HIV & Aids - presentation
Culture. By: Julie R. & Haley B.. Religion. The main religion that is dominant with Aids is . Islamic. . The main religion in Africa is . Islamic, . which many cases are found in that country. . Ethnicity and Religion Continued.
Readiness for antiretroviral therapy: implications for link - presentation
Brendan . Maughan-Brown. Southern Africa . Labour. and Development Research Unit (SALDRU. ) . University . of Cape Town. Philip Smith, Linda-Gail . Bekker. The Desmond Tutu HIV Centre, University of Cape Town .
Antiretroviral Updates: - presentation
New Treatments for HIV. C. Ryan Tomlin, . Pharm.D. ., BCPS, AAHIVP. Mercy Health Saint Mary’s. Grand Rapids, Michigan. Outline. Newly Released Antiretroviral Medications. Isentress. HD. ® (. raltegravir.
Managing Antiretroviral Failure in 2012 - presentation
Jennifer Hoy. , MBBS. Professor of Medicine. Director, HIV Medicine. The Alfred Hospital. FINAL: 07-20-12. Phillip, Aged 67 Years. HIV infection diagnosed on screening for HBV treatment trial in 1995.
W orking with Different Groups - presentation
W orking with Different Groups Module 3 (e) Serodiscordant Couples and PrEP PrEP and S erodiscordant Couples PrEP for…. HIV-negative partners offers an additional tool to reduce the risk of sexual transmission, particularly if
M ulti- m onth prescription of antiretroviral therapy amongst - presentation
children and . adolescents: experiences from the Baylor . International Pediatric AIDS initiative (BIPAI) . in six African countries. IAS . Conference, July 24, 2017. Abstract number: . MOAD0105. . R.S.